Topline results were announced from a phase 3 trial evaluating Cylembio (imsapepimut and etimupepimut, adjuvanted) in combination with pembrolizumab as a first-line treatment for advanced melanoma.

Patients with advanced desmoplastic melanoma have high response to single-agent anti-programmed death protein 1 (PD-1) ...

Personalized vaccines are currently being investigated for the treatment of patients with kidney cancer; however, the ...

PD-1 Inhibitor Drug PD-1 Inhibitor Drugs Market poised for robust growth, driven by rising cancer therapies and expanding immuno-oncology a ...

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ('Kelun-Biotech', HKEX: 6990) announced that clinical data from a Phase II study evaluating novel TROP2 antibody-drug conjugate (ADC) sacituzumab ...

Breast cancer is the second most common cancer among women and the second leading cause of cancer-related deaths among women in the US. In light of Breast Cancer Research Awareness Day, The American ...

A woman from Harrogate is embarking on an epic cycling journey from Land’s End to John o’Groats to honour her late husband.

AEMD READ THE FULL AEMD RESEARCH REPORT ENROLLMENT FOR ONCOLOGY TRIAL COHORT 2 HAS COMMENCED Data Safety Monitoring Board Recommended AEMD Progress Trial Without Modification Aethlon Medical ...

Promising Anaplastic Thyroid Cancer Pipeline Therapies such as Pembrolizumab, Lenvatinib, Nivolumab, Sorafenib (Nexavar,BAY43 ...

Harrogate resident, Jackie Swainston, is taking on an epic Land’s End to John o’Groats cycling challenge on 7 September 2025 ...

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or ...